As a specific inhibitor of HMGCR, statins are extensively used as a cholesterol-lowering agents.11 Although several phase 1/2 clinical trials have demonstrated that statins can improve the efficacy of standard therapy in AML,12,13 leukemia cells actually display a heterogenous response to statins.14,15 Thus, enzymes other than HMGCR can be potential targets, and increasing studies are focusing on enzymes that control cholesterol synthesis.16 We approached this question by profiling gene expression differences between complete remission (CR) and RR patients using RNA-seq. This evidence concerns the gene HMGCR and leukemia.